ArticleCureus2025
Cognitive Decline in Hemodialysis Patients: A Cross-Sectional Study Using Addenbrooke's Cognitive Examination-III (ACE-III).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Among patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis (HD), cognitive impairment (CI) is a significant yet often unknown side effect. This study used Addenbrooke's Cognitive Examination-III (ACE-III) to assess the prevalence and pattern of cognitive dysfunction in a South Indian HD population. It also aimed to determine the correlations with clinical and sociodemographic factors. Methods A cross-sectional study was conducted in a tertiary care facility in Chennai, Tamil Nadu, India, involving 175 patients undergoing maintenance HD for more than three months. The Indian English version of the ACE-III was used to evaluate cognitive function. Clinical and demographic data, including age, gender, education, duration of dialysis, comorbidities, and hemoglobin levels, were collected and analyzed. A p-value of <0.05 was considered statistically significant. Results Almost half of the patients, that is, 82 (46.9%), were classified as having CI with ACE-III scores of 60-80. Lower cognitive scores were significantly associated with greater age, lower educational levels, and longer time spent on dialysis (p<0.05). Conclusion In South India, CI is prevalent among HD patients, with memory and attention being the areas that are most affected. Age, level of education, and dialysis duration are contributing factors. In dialysis care, routine ACE-III screening can facilitate early detection and targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.